Premium
Clinicopathological significance of RCAN2 production in gastric carcinoma
Author(s) -
Hattori Yui,
Sentani Kazuhiro,
Shinmei Shunsuke,
Oo Htoo Zarni,
Hattori Takuya,
Imai Takeharu,
Sekino Yohei,
Sakamoto Naoya,
Oue Naohide,
Niitsu Hiroaki,
Hinoi Takao,
Ohdan Hideki,
Yasui Wataru
Publication year - 2019
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.13764
Subject(s) - transfection , small interfering rna , cancer research , immunohistochemistry , rna , cancer , biology , cell growth , cell culture , protein kinase b , microbiology and biotechnology , medicine , pathology , gene , phosphorylation , biochemistry , genetics
Aims Gastric cancer ( GC ) is one of the leading causes of cancer‐related death worldwide. Genes expressed only in cancer tissue may be useful biomarkers for cancer diagnosis and therapeutics. The aims of the present study were to analyse regulator of calcineurin 2 ( RCAN 2) in a large number of GC s, and to investigate how these expression patterns correlate with clinicopathological parameters and various markers. Methods and results An immunohistochemical analysis of RCAN 2 in 207 GC tissue samples showed that 110 (53%) GC s were positive for RCAN 2. RCAN 2‐positive GC s were more advanced in terms of TNM classification and tumour stage than RCAN 2‐negative GC s. Furthermore, RCAN 2 was an independent prognostic classifier for GC patients. The cell growth and invasiveness of RCAN 2 small interfering RNA (si RNA )‐transfected GC cell lines were less than those of the negative control si RNA ‐transfected cell lines, whereas those of RCAN 2 ‐transfected cells were significantly increased as compared with those of empty vector‐transfected cells. RCAN 2 si RNA inhibits the phosphorylation of AKT and p44/p42 ( ERK 1/2). RCAN 2 was colocalised with EGFR , nuclear β‐catenin, MMP 7, laminin‐γ2, VEGF ‐A, and VEGF ‐C. Conclusion These results suggest that RCAN 2 is involved in tumour progression and is an independent prognostic classifier in patients with GC .